Work

AVB-500, a receptor tyrosine kinase AXL inhibitor, in combination with olaparib improves response in uterine serous cancer

Year: 2021

Type: article

Source: Gynecologic Oncology

DOI: 10.1016/s0090-8258(21)00825-8

Authors: Michael Toboni, Mary Mullen, Joan Tankou, Hollie Noia, Alyssa Oplt, Lindsay Kuroki, Andrea Hagemann, Carolyn McCourt, Premal Thaker, David Mutch, Dineo Khabele, Matthew Powell, Katherine Fuh

Institution: Washington University in St. Louis

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3194549795

FWCI:

Cites:

Cited by:

Related to: 10